Association study of the platelet collagen receptor glycoprotein VI gene with rheumatoid arthritis

Laetitia Michou1, Francois Cornélis, Morgane Baron

  • 1Department of Medicine, Faculté de Médecine de l'Université Laval, CHUQ Research center and Division of Rheumatology, CHUQ, Quebec City, QC, Canada. laetitia.michou@crchul.ulaval.ca.

Abstract

Insights

Platelet glycoprotein VI (GPVI) gene single nucleotide polymorphisms (SNPs) were investigated for association with rheumatoid arthritis (RA). No significant link was found between GPVI haplotypes and RA susceptibility, suggesting GPVI

Area of Science:

  • Immunology
  • Genetics
  • Rheumatology

Background:

  • Platelets, beyond hemostasis, play a role in immunity, releasing microparticles upon activation of the glycoprotein VI (GPVI) receptor.
  • These microparticles are implicated in amplifying inflammation in rheumatoid arthritis (RA).
  • GPVI gene polymorphisms, specifically single nucleotide polymorphisms (SNPs), are known and linked to cardiovascular risk.

Purpose of the Study:

  • To investigate the association between GPVI gene haplotypes and rheumatoid arthritis (RA).
  • To determine if the minor GPVI haplotype, associated with cardiovascular risk, also confers susceptibility to RA.

Main Methods:

  • Genotyping of five non-synonymous SNPs defining GPVI haplotypes (rs1613662, rs1654416, rs2304167, rs1654413, rs1671152) in 399 RA patients and their parents.
  • Utilized the transmission disequilibrium test (TDT) via the FBAT program for statistical analysis.
  • Haplotypes were estimated using the FBAT program.

Main Results:

  • No statistically significant transmission disequilibrium was observed for the tested GPVI SNPs.
  • The major TAAC haplotype (SKTQH isoform) was found in 78% of individuals, and the CGGA haplotype (PEALN isoform) in 8%.
  • No association was found between GPVI gene haplotypes and rheumatoid arthritis (RA).

Conclusions:

  • The tested single nucleotide polymorphisms (SNPs) within the GPVI gene are not associated with RA susceptibility or severity.
  • Platelet GPVI may contribute to arthritis pathogenesis through mechanisms independent of its gene polymorphism.

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...